Develops and markets orthobiological injection solutions and joint supplements.

Aptissen SA

Plan-les-Ouates (HQ) · Milano · Warszawa · Dijon · Freising · Rio de JaneiroNew on Amplifa

2013Founded (spin-off of Anteis)

Aktiengesellschaft (SA)Legal form

6 locationsHQ and 5 subsidiaries

>50 countriesSales countries

About Aptissen

Aptissen SA is a Swiss medical technology company founded in 2013 as a spin-off of Anteis, headquartered in Plan-les-Ouates near Geneva. The company specializes in orthobiological solutions for joint diseases and develops and markets the patented viscosupplement Synolis, an injectable gel based on hyaluronic acid and sorbitol, as well as, since 2019, the drinkable dietary supplement Cartylis. Distribution is handled through a worldwide network of local distribution partners in more than 50 countries, including Switzerland, France, Italy, Poland, Canada, Mexico, Brazil, the UAE, Singapore and Malaysia. In addition to distribution, Aptissen offers in- and out-licensing of products, patents and technologies, support for research activities, and training through the Aptissen Academy. The company maintains subsidiaries in Italy, Poland, France, Germany and Brazil and is certified according to ISO 13485:2016 as well as MDSAP.

Site: Plan-les-Ouates
Processes: Distribution via worldwide distributor network (>50 countries), In-/out-licensing of products, patents and technologies, Support for research activities, Training (Aptissen Academy)
Materials: Hyaluronic acid, Sorbitol, Collagen synthesis promotion
Certificates: ISO 13485:2016, MDSAP (Canada, Brazil)
Founded: 2013
Industries: Medical technology/orthobiologics, Orthopedics, Sports medicine, Dietary supplements

01
Research and development
02
In- and out-licensing of products, patents and technologies
03
Regulatory approval (CE, MDSAP)
04
Distribution via worldwide distributor network
05
Training (Aptissen Academy)

Products and Technologies

Hyaluronic acid

Active ingredient of the patented injectable viscosupplement Synolis for pain relief in osteoarthritis.

Sorbitol

Second component of the patented Synolis gel with crossover frequency and concentration.

Kollagen

Collagen synthesis promotion

Mode of action of the drinkable dietary supplement Cartylis for supporting the joints.

Locations

Plan-les-Ouates (HQ)

Headquarters

Milano

Subsidiary Aptissen Italia S.r.l.

Warszawa

Subsidiary Aptissen Polska Sp. z o.o.

Dijon

Subsidiary Aptissen France

Freising

Subsidiary Aptissen GmbH

Rio de Janeiro

Subsidiary Aptissen Brazil

Products

**Synolis VA 40/80**Viscosupplement · Orthopedics

**Synolis VA 80/160**Viscosupplement · Orthopedics

**Cartylis**Dietary supplement · Joint health

Inside the production

Aptissen – orthobiological solutions for joints

Industries

Medical technology/orthobiologicsOrthopedicsSports medicineDietary supplements

Additional services

Distribution via worldwide distributor network (>50 countries)In-/out-licensing of products, patents and technologiesSupport for research activitiesTraining (Aptissen Academy)

Quality

Quality has top priority at Aptissen, as the company is committed to the well-being of every person who uses its products. The company is certified according to ISO 13485:2016 and recognized under MDSAP for Canada and Brazil.

Evidence	Plan-les-Ouates
ISO 13485:2016
MDSAP (Canada, Brazil)

History

2009
Market launch of Synolis VA 40/80; European patent on crossover frequency and concentration
2013
Founding of Aptissen as a spin-off of Anteis
2015
Subsidiary in Italy
2018
ISO 13485:2016; subsidiary in Poland
2019
Market launch of Synolis VA 80/160 with CE marking; subsidiary in France
2020
MDSAP (Canada, Brazil); market launch of Cartylis
2023
Subsidiaries in Germany and Brazil